Generex Biotechnology Corporation (GNBT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Generex Biotechnology Corporation (GNBT) trades at $0.0006 with AI Score 50/100 (Grade B). GenBioTech, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for GNBT: GNBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GNBT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
GNBT: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Generex Biotechnology Corporation (GNBT) Healthcare & Pipeline Overview
GenBioTech, Inc. is a biotechnology firm specializing in targeted cancer therapies, with its lead compound CLL-I showing promise in preclinical studies. The company operates within the competitive biotechnology sector, focusing on innovative treatments with reduced side effects compared to traditional chemotherapy.
What Is the Investment Thesis for GNBT?
GenBioTech presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's lead drug candidate, CLL-I, holds significant potential in the treatment of various cancers, but its success is contingent on positive outcomes from preclinical and future clinical trials. Key value drivers include the successful completion of preclinical studies, initiation of Phase 1 clinical trials, and potential partnerships with larger pharmaceutical companies. The investment thesis hinges on the ability of CLL-I to demonstrate superior efficacy and safety compared to existing cancer therapies. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies with greater resources. The company's financial performance and stock valuation will be closely tied to the progress of CLL-I through the development pipeline.
Based on FMP financials and quantitative analysis
GNBT Key Highlights
- Lead drug candidate CLL-I targets specific molecular pathways involved in cancer cell growth and survival.
- Preclinical studies have demonstrated promising efficacy and safety profile for CLL-I.
- GenBioTech focuses on developing targeted therapies that selectively eliminate cancer cells while sparing healthy tissues.
- The company aims to address unmet medical needs in oncology, particularly in cancers resistant to conventional therapies.
- GenBioTech's success depends on positive outcomes from preclinical and future clinical trials of CLL-I.
Who Are GNBT's Competitors?
GNBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $481.72 | +0.25% | $122B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $675.02 | +0.43% | $69.5B | 92 |
| ALNY Alnylam Pharmaceuticals, Inc. | $272.67 | +1.94% | $36.4B | 95 |
| RPRX Royalty Pharma plc | $57.63 | +0.58% | $24.8B | 81 |
| INCY Incyte Corporation | $115.65 | -1.36% | $23.1B | 99 |
| UTHR United Therapeutics Corporation | $529.34 | -1.18% | $22.5B | 99 |
| NBIX Neurocrine Biosciences, Inc. | $173.00 | +1.24% | $18.0B | 95 |
| EXEL Exelixis, Inc. | $55.53 | -0.70% | $14.0B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GNBT's Key Strengths?
- Innovative technology platform for developing targeted cancer therapies.
- Promising preclinical data for CLL-I.
- Experienced management team with expertise in cancer biology and drug development.
- Strong intellectual property protection for CLL-I.
What Are GNBT's Weaknesses?
- Limited financial resources.
- Early-stage development of CLL-I.
- Dependence on successful clinical trials and regulatory approval.
- Lack of commercial infrastructure.
What Could Drive GNBT Stock Higher?
- Initiation of Phase 1 clinical trials for CLL-I.
- Presentation of preclinical data at scientific conferences.
- Continued research and development of CLL-I.
- Exploration of strategic partnerships and collaborations.
What Are the Key Risks for GNBT?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- Dependence on successful clinical trials and regulatory approval.
What Are the Growth Opportunities for GNBT?
- Expansion of CLL-I's therapeutic applications: GenBioTech can explore the potential of CLL-I in treating various cancer types beyond its initial target. This could significantly broaden the market opportunity for CLL-I and increase its commercial potential.
- Strategic partnerships and collaborations: GenBioTech can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of CLL-I. Collaborations can provide access to funding, expertise, and distribution channels, enhancing the company's ability to bring CLL-I to market. The pharmaceutical industry is increasingly relying on partnerships to drive innovation and expand their product portfolios.
- Development of companion diagnostics: GenBioTech can develop companion diagnostics to identify patients who are most likely to respond to CLL-I. This would improve the efficacy of CLL-I and reduce the risk of adverse events. The market for companion diagnostics is growing rapidly, driven by the increasing adoption of personalized medicine.
- Expansion into international markets: GenBioTech can expand its research and development activities and commercial operations into international markets. This would provide access to new patient populations and revenue streams. The global market for cancer therapeutics is growing rapidly, particularly in emerging economies.
- Acquisition of complementary technologies or assets: GenBioTech can acquire complementary technologies or assets to enhance its research and development capabilities and expand its product pipeline. This could include acquiring other biotechnology companies or licensing new drug candidates. The biotechnology industry is characterized by frequent mergers and acquisitions, as companies seek to consolidate their market position and expand their product offerings.
What Opportunities Does GNBT Have?
- Expansion of CLL-I's therapeutic applications.
- Strategic partnerships with larger pharmaceutical companies.
- Development of companion diagnostics.
- Expansion into international markets.
What Threats Does GNBT Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established pharmaceutical companies.
- Patent challenges.
What Are GNBT's Competitive Advantages?
- Proprietary technology platform for developing targeted cancer therapies.
- Strong intellectual property protection for CLL-I and other drug candidates.
- Expertise in cancer biology and drug development.
- Established relationships with key opinion leaders in oncology.
What Does GNBT Do?
GenBioTech, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. Founded with the mission of improving patient outcomes and quality of life, GenBioTech focuses on creating targeted therapies that selectively eliminate cancer cells while sparing healthy tissues. The company's lead drug candidate, CLL-I, represents a new approach to cancer treatment by targeting specific molecular pathways involved in cancer cell growth and survival. CLL-I is currently in preclinical development, with promising results demonstrating its efficacy and safety profile. GenBioTech's research and development efforts are centered on addressing unmet medical needs in oncology, particularly in cancers that are resistant to conventional therapies. The company operates primarily in the United States, with plans to expand its research and development activities globally through strategic partnerships and collaborations. GenBioTech's competitive positioning lies in its innovative approach to cancer treatment, focusing on targeted therapies that offer improved efficacy and reduced toxicity compared to traditional chemotherapy and radiation.
What Products and Services Does GNBT Offer?
- Develop novel therapies for cancer treatment.
- Focus on targeted therapies that selectively eliminate cancer cells.
- Conduct preclinical research to evaluate the efficacy and safety of drug candidates.
- Pursue clinical trials to assess the safety and efficacy of drug candidates in humans.
- Seek regulatory approval for new cancer therapies.
- Commercialize and market approved cancer therapies.
How Does GNBT Make Money?
- Develop and license novel cancer therapies.
- Generate revenue through sales of approved cancer therapies.
- Collaborate with pharmaceutical companies for research and development.
- Seek funding through grants, venture capital, and public offerings.
What Industry Does GNBT Operate In?
GenBioTech operates within the highly competitive biotechnology industry, which is characterized by rapid innovation, intense competition, and significant regulatory oversight. GenBioTech's focus on targeted cancer therapies positions it within a growing segment of the oncology market, where there is a strong need for more effective and less toxic treatments. The company faces competition from established pharmaceutical companies, as well as other biotechnology firms developing innovative cancer therapies. Success in this industry requires significant investment in research and development, strong intellectual property protection, and the ability to navigate complex regulatory pathways.
Who Are GNBT's Key Customers?
- Cancer patients
- Oncologists
- Hospitals and cancer centers
- Pharmaceutical companies
GNBT Valuation & Market Position
Relative to its peer group, GNBT's quantitative score of 50/100 is below the peer average of 93/100.
ROE 217%Key Financial Metrics
Return on equity for Generex Biotechnology Corporation stands at 216.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -73.5%, showing how much profit it generates from its asset base. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
GNBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative technology platform for developing targeted cancer therapies.
- Promising preclinical data for CLL-I.
- Experienced management team with expertise in cancer biology and drug development.
- Strong intellectual property protection for CLL-I.
Bear Case
- Limited financial resources.
- Early-stage development of CLL-I.
- Dependence on successful clinical trials and regulatory approval.
- Lack of commercial infrastructure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
GNBT Latest News
No recent news available for GNBT.
GNBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GNBT.
Price Targets
Wall Street price target analysis for GNBT.
GNBT MoonshotScore
What does this score mean?
The MoonshotScore rates GNBT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
GNBT OTC Market Information
GNBT trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
What Investors Ask About Generex Biotechnology Corporation (GNBT) — Healthcare
What does the AI Score mean for GNBT?
GNBT holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. GenBioTech, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. The company's lead drug candidate, CLL-I, is designed to target …
What does GNBT do?
GenBioTech, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. Their primary focus is on targeted therapies that selectively eliminate cancer cells while minimizing harm to healthy cells. The company's lead drug candidate, CLL-I, is designed to target specific molecular pathways involved in cancer cell growth and survival, offering a potentially more effective and less toxic approach to cancer treatment compared to traditional methods.
What do analysts say about GNBT stock?
Analyst coverage of GenBioTech stock is currently limited due to the company's early stage of development and small market capitalization. However, analysts who follow the company closely are focused on the progress of CLL-I through preclinical and clinical trials.
What are the main risks for GNBT?
The main risks for GenBioTech include the inherent uncertainties associated with drug development, such as the possibility of clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies with greater resources. The company's limited financial resources also pose a risk, as it may need to raise additional capital to fund its research and development activities.
What are the key factors to evaluate for GNBT?
Generex Biotechnology Corporation (GNBT) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does GNBT data refresh on this page?
GNBT's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven GNBT's recent stock price performance?
Generex Biotechnology Corporation (GNBT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for developing targeted cancer therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GNBT overvalued or undervalued right now?
Generex Biotechnology Corporation (GNBT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GNBT before investing?
Before investing in Generex Biotechnology Corporation (GNBT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited publicly available data.
- The company is in an early stage of development, and its future prospects are highly uncertain.